CNTB Connect Biopharma Holdings Ltd stock chart & analysis
Conviction 40HealthcareScan · Thu, Nov 19, 2026Connect Biopharma Holdings Ltd (CNTB) closed at $0.6203 (-6.75%) on Nov 19, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 33, RS Rating 6, -83.8% from its 52-week high, -78.0% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why CNTB moved
From the StockSetups movers recaps that covered CNTB, newest first. A recap states what was known that day.
- Premarket+84.0%
The catalyst is clear. Connect Biopharma announced positive preliminary topline data from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD (chronic obstructive pulmonary disease) and Type 2 inflammation.
Premarket Movers Sept 30, 2026: CNTB, LGHL, VBIO →
Financials as of Wed, Sep 30, 2026 · quarterly.
CNTB technical analysis
Trend
CNTB is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 33.6% below the 50-day ($0.9339) and 70.0% below the 200-day ($2.07). ADX(14) at 18 points to a weak trend — more range than direction. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 33, in the bearish half of its range. The MACD histogram is positive. A bullish MACD divergence is in place. Its RS Rating of 6 puts its weighted 12-month performance ahead of about 6% of the US market.
Volume and volatility
It trades about $445,899 a day on average. ATR(14) is $0.0823, 13.3% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.09) shows distribution.
Key levels
The chart pattern's support is $0.6409 and its resistance $1.40. The 52-week range is $0.5500 to $3.82; price is 83.8% below the high and 12.8% above the low. The VWAP anchored at the 52-week high is $1.47, above price.
Performance
CNTB returned -6.8% (1 week), -22.3% (1 month), -73.7% (3 months), -73.7% (6 months), -75.9% (1 year), -78.0% (year to date).
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Pharmaceutical Preparations · Listed 2025 · 64 employees
Recent news
- Piper Sandler cuts Connect Biopharma stock price target on launch delayInvesting.com · Tue, Nov 17, 2026
- Connect Biopharma Holdings Limited Stock 12‑Month Price Target Cut to $5.73, Implies 791% UpsideTradingView · Tue, Nov 17, 2026
- A fund manager reports a 2.16 million-share passive stake in Connect Biopharma (CNTB).Stock Titan · Mon, Nov 16, 2026
- Connect Biopharma Q3 2026 Earnings Results and ReportMarketBeat · Mon, Nov 16, 2026
- Connect Biopharma Receives Nasdaq Minimum Bid Price Compliance NoticeTipRanks · Mon, Nov 16, 2026
- After $44M in nine-month operating cash use, Connect Biopharma (CNTB) needs more capital.Stock Titan · Mon, Nov 16, 2026
- CNTB: Connect Biopharma Holdings Limited filed SEC Form 8-K...Quantisnow · Mon, Nov 16, 2026
- Connect Biopharma reports Q3 EPS (26c), consensus (26c)TipRanks · Mon, Nov 16, 2026
- Connect Biopharma Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026www.marketscreener.com · Mon, Nov 16, 2026
- Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance · Mon, Nov 16, 2026
Insider activity
SEC Form 4 transactions in CNTB · open-market 1 buy
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Huang James Director · Ordinary Shares · 2026-05-29 | Buy | 150K | $372K | 2026-05-29 | 2026-06-02 |
SEC filings
EDGAR filings in CNTB · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.